New Emerging Aspect of Herbal Extracts for the Treatment of Osteoporosis: Overview

Overview

Journal Curr Rheumatol Rev

Publisher Bentham Science Publishers

Specialty Rheumatology

Date 2024 Jan 4

PMID 38173067

Authors

Priyanka Kumari

Raj K Shirumalla

Vijay Bhalla

Md Sabir Alam

Affiliations

Soon will be listed here.

Abstract

As the global population ages, osteoporosis is becoming a more common silent disease. Osteoporosis is characterized by decreased bone quality and strength, which increases the risk of fragility fractures in the elderly. According to estimates, 50% of women eventually suffer from an osteoporotic fracture. Due to increasing disability, more frequent hospital hospitalizations, and most critically, fragility fractures have been linked to a reduced quality of life. Osteoporotic fractures have been linked to an increased mortality risk; and must be considered in awareness as a serious health concern. There are anti-osteoporotic medications available that improve bone quality. Considering the availability of various treatment options, still there are a lot of underserved needs in the treatment of fractures and osteoporosis. For example, the application of natural products and herbal resources for fracture healing, because of the androgen-like and antioxidant characteristics of the plants, they can play a crucial for accelerating the repair of bone fractures. In this article, we'll discuss the herbal remedies that are essential for treating osteoporosis (bone disease).

References

Alshahrani F, Alsulaiman Y, Almashari Y, Alawad N, Almousa S, Allarakia Y . Use of the Osteoporosis Self-Assessment Tool as a Screening Tool for Osteoporosis in Saudi Postmenopausal Women. Cureus. 2023; 15(4):e37755. PMC: 10193514. DOI: 10.7759/cureus.37755. View

Waugh E, Lam M, Hawker G, McGowan J, Papaioannou A, Cheung A . Risk factors for low bone mass in healthy 40-60 year old women: a systematic review of the literature. Osteoporos Int. 2008; 20(1):1-21. PMC: 5110317. DOI: 10.1007/s00198-008-0643-x. View

Ray N, Chan J, Thamer M, Melton 3rd L . Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997; 12(1):24-35. DOI: 10.1359/jbmr.1997.12.1.24. View

Kanis J, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A . Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int. 2000; 11(8):669-74. DOI: 10.1007/s001980070064. View

Reginster J . Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs. 2010; 71(1):65-78. DOI: 10.2165/11587570-000000000-00000. View

Genant H, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J . Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int. 2000; 10(4):259-64. DOI: 10.1007/s001980050224. View

Diez-Perez A, Naylor K, Abrahamsen B, Agnusdei D, Brandi M, Cooper C . International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int. 2017; 28(3):767-774. PMC: 5302161. DOI: 10.1007/s00198-017-3906-6. View

Kanis J, Norton N, Harvey N, Jacobson T, Johansson H, Lorentzon M . SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos. 2021; 16(1):82. PMC: 8172408. DOI: 10.1007/s11657-020-00871-9. View

Resal T, Mango K, Bacsur P, Szanto K, Pigniczki D, Keresztes C . Possible genetical predictors of efficacy and safety of budesonide-MMX in patients with mild-to-moderate ulcerative colitis, and safety comparison with methylprednisolone. Expert Opin Drug Saf. 2023; 22(6):517-524. DOI: 10.1080/14740338.2023.2181336. View

10.

Yan C, Zhang J, An F, Wang J, Shi Y, Yuan L . Research Progress of Ferroptosis Regulatory Network and Bone Remodeling in Osteoporosis. Front Public Health. 2022; 10:910675. PMC: 9280046. DOI: 10.3389/fpubh.2022.910675. View

11.

Christiansen C . Prevention and treatment of osteoporosis with hormone replacement therapy. Int J Fertil Menopausal Stud. 1993; 38 Suppl 1:45-54. View

12.

Eisman J . Genetics of osteoporosis. Endocr Rev. 1999; 20(6):788-804. DOI: 10.1210/edrv.20.6.0384. View

13.

Gilsanz V, Kovanlikaya A, Costin G, Roe T, Sayre J, Kaufman F . Differential effect of gender on the sizes of the bones in the axial and appendicular skeletons. J Clin Endocrinol Metab. 1997; 82(5):1603-7. DOI: 10.1210/jcem.82.5.3942. View

14.

Leung P, Siu W . Herbal treatment for osteoporosis: a current review. J Tradit Complement Med. 2014; 3(2):82-7. PMC: 3924968. DOI: 10.4103/2225-4110.110407. View

15.

Zhang N, Han T, Huang B, Rahman K, Jiang Y, Xu H . Traditional Chinese medicine formulas for the treatment of osteoporosis: Implication for antiosteoporotic drug discovery. J Ethnopharmacol. 2016; 189:61-80. DOI: 10.1016/j.jep.2016.05.025. View

16.

Norazlina M, Ima-Nirwana S, Abul Gapor M, Abdul Kadir Khalid B . Tocotrienols are needed for normal bone calcification in growing female rats. Asia Pac J Clin Nutr. 2002; 11(3):194-9. DOI: 10.1046/j.1440-6047.2002.00290.x. View

17.

French D, Muir J, Webber C . The ovariectomized, mature rat model of postmenopausal osteoporosis: an assessment of the bone sparing effects of curcumin. Phytomedicine. 2008; 15(12):1069-78. DOI: 10.1016/j.phymed.2008.06.007. View

18.

Li X, Zhang H . Synergy in natural medicines: implications for drug discovery. Trends Pharmacol Sci. 2008; 29(7):331-2. DOI: 10.1016/j.tips.2008.04.002. View

19.

Lagari V, Levis S . Phytoestrogens and bone health. Curr Opin Endocrinol Diabetes Obes. 2010; 17(6):546-53. DOI: 10.1097/MED.0b013e32833f4867. View

20.

Liang W, Yew D, Hon K, Wong C, Kwok T, Leung P . Indispensable value of clinical trials in the modernization of traditional Chinese medicine: 12 years' experience at CUHK and future perspectives. Am J Chin Med. 2014; 42(3):587-604. DOI: 10.1142/S0192415X14500384. View